Johnson & Johnson (J&J) is an American multinational corporation founded in 1886, known for its consumer health products, medical devices, and pharmaceuticals. This timeline traces its evolution from a small surgical dressing company to a global healthcare giant, highlighting key product launches, acquisitions, leadership changes, and legal challenges.
Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson found Johnson & Johnson in New Brunswick, New Jersey, to produce surgical dressings. The company starts with 14 employees. #healthcare #history
J&J introduces its first product, a ready-made surgical dressing kit, inspired by Robert Wood Johnson's observation of unsanitary medical conditions. This marks the beginning of the company's focus on sterile medical supplies. #innovation #medical
J&J launches its iconic Johnson's Baby Powder, a talc-based product that becomes a household name. The brand later faces legal challenges over asbestos contamination. #consumer #products
Earle Dickson invents the Band-Aid for his wife, and J&J begins mass production. The product revolutionizes home first aid and becomes one of the most recognized brands worldwide. #invention #health
Johnson & Johnson lists on the New York Stock Exchange, raising capital for expansion. The IPO helps fund research and international growth. #finance #business
J&J acquires McNeil Laboratories, gaining access to over-the-counter drugs like Tylenol (acetaminophen). This marks J&J's entry into the pharmaceutical sector. #acquisition #pharma
J&J begins research into contact lenses, leading to the launch of Acuvue in 1987 by its subsidiary Vistakon. Acuvue becomes the world's first disposable contact lens. #health #technology
Robert Wood Johnson II writes the Johnson & Johnson Credo, a four-paragraph statement outlining the company's responsibilities to customers, employees, communities, and shareholders. It becomes a guiding principle for corporate decision-making. #ethics #leadership
J&J's subsidiary DePuy (acquired in 1998) receives FDA approval for a hip replacement implant. This marks J&J's entry into orthopedics, later a major business segment. #medicaldevices #surgery
Seven people die after taking cyanide-laced Tylenol capsules. J&J recalls 31 million bottles, introduces tamper-evident packaging, and launches a massive PR campaign. The crisis response becomes a benchmark for corporate responsibility. #crisis #consumer
Vistakon, a J&J subsidiary, introduces Acuvue, the world's first disposable contact lens. The product revolutionizes eye care and becomes a billion-dollar brand. #innovation #health
J&J acquires Neutrogena Corporation, expanding its consumer skincare portfolio. The brand is known for its mild soap and dermatological products. #acquisition #beauty
J&J buys Cordis, a leader in cardiovascular medical devices, including stents and catheters. This strengthens J&J's position in interventional cardiology. #medicaldevices #acquisition
J&J acquires DePuy, Inc., a leading orthopedic and neurological device company. DePuy later faces litigation over metal-on-metal hip implants. #acquisition #orthopedics
J&J acquires Centocor, a biotechnology company, for $4.9 billion. This brings the blockbuster drugs Remicade (infliximab) and later Stelara (ustekinumab) into the pipeline. #biotech #pharma
J&J receives FDA approval for Risperdal (risperidone), an antipsychotic drug. It becomes a top-selling drug, but later faces lawsuits over off-label marketing and side effects. #pharma #mentalhealth
J&J acquires Pfizer's consumer healthcare business for $16.6 billion, adding brands like Listerine, Nicorette, and Sudafed. This consolidates J&J's position in over-the-counter products. #acquisition #consumer
J&J buys Conor Medsystems for its drug-eluting stent technology. The deal enhances J&J's cardiovascular device portfolio amidst competition from Boston Scientific and Abbott. #acquisition #medicaldevices
J&J acquires an 18% stake in Elan Corporation and later buys Dutch vaccine maker Crucell for $2.4 billion. These moves expand J&J's presence in neurology and vaccines. #biotech #vaccines
DePuy Orthopaedics recalls its ASR XL Acetabular System and ASR Hip Resurfacing System after high failure rates. Thousands of patients file lawsuits, leading to billions in settlements. #recall #medicaldevices
J&J acquires Synthes, the world's largest orthopedic trauma device company, for $19.7 billion. The merger creates the largest orthopedic business globally. #acquisition #orthopedics
J&J agrees to pay $1.1 billion to settle most U.S. lawsuits over its recalled DePuy hip implants. The settlement covers about 8,000 patients. #legal #medicaldevices
J&J acquires Aragon Pharmaceuticals for its prostate cancer drug candidate, apalutamide (Erleada). The deal strengthens J&J's oncology pipeline. #pharma #cancer
J&J agrees to a $2.2 billion settlement with the U.S. Department of Justice for improper marketing of the antipsychotic drug Risperdal. The settlement includes criminal and civil penalties. #legal #pharma
J&J acquires Novira Therapeutics, a company developing treatments for hepatitis B virus (HBV). The deal expands J&J's infectious disease portfolio. #biotech #pharma
J&J acquires Abbott Medical Optics (AMO) for $4.33 billion, gaining a leading position in eye health, including cataract surgery and laser vision correction. #acquisition #eyehealth
J&J's Stelara (ustekinumab) receives FDA approval for the treatment of Crohn's disease. The drug, originally approved for psoriasis, becomes a blockbuster in immunology. #pharma #immunology
J&J completes its $30 billion acquisition of Actelion, a Swiss biotech specializing in pulmonary arterial hypertension (PAH) drugs. The deal includes a spin-off of Idorsia. #acquisition #biotech
J&J acquires Auris Health, a robotics company, for $3.4 billion, gaining the Monarch platform for robotic bronchoscopy. This marks J&J's entry into surgical robotics. #robotics #medicaldevices
Janssen Pharmaceuticals, a J&J subsidiary, begins development of a single-dose COVID-19 vaccine using adenovirus vector technology. The vaccine receives emergency use authorization in February 2021. #vaccine #pandemic
The U.S. Food and Drug Administration grants emergency use authorization for the Johnson & Johnson COVID-19 vaccine, the third approved vaccine in the U.S. It offers single-dose convenience. #vaccine #health
The CDC and FDA recommend a pause in J&J vaccine administration after reports of rare blood clots. The pause lasts 10 days; the vaccine resumes with a warning label. #vaccine #safety
J&J announces plans to split into two publicly traded companies: one focused on pharmaceuticals and medical devices (J&J), and another on consumer health products (Kenvue). The move aims to streamline operations. #corporate #restructuring
J&J announces the sale of its diabetes care business, including LifeScan and Animas, to Verily Life Sciences for $2.5 billion. The divestiture is part of J&J's portfolio rationalization. #divestiture #diabetes
Johnson & Johnson faces over 38,000 lawsuits alleging its talc-based baby powder caused ovarian cancer and mesothelioma. The company stops selling talc-based powder in the U.S. and Canada in 2020, but litigation continues. #legal #consumer
Kenvue Inc., the consumer health business of J&J, begins trading on the NYSE after the largest IPO spin-off in a decade. J&J retains a 9.5% stake. The separation is completed in 2023. #spin-off #consumer
J&J proposes an $8.9 billion settlement to resolve all current and future talc lawsuits. The settlement plan involves a subsidiary filing for bankruptcy. The deal is pending court approval as of 2024. #legal #settlement
J&J acquires Shockwave Medical, a leader in intravascular lithotripsy technology for treating calcified coronary artery disease, for $13.1 billion. The deal boosts J&J's cardiovascular device business. #acquisition #medicaldevices
J&J acquires Yellow Jersey Therapeutics, gaining rights to a Phase 2 monoclonal antibody for chronic rhinosinusitis with nasal polyps. The deal expands J&J's respiratory portfolio. #acquisition #pharma
J&J acquires Proteologix, a biotech developing bispecific antibodies for atopic dermatitis and asthma. The deal strengthens J&J's immunology pipeline. #acquisition #biotech
After the separation of Kenvue, the remaining company continues as Johnson & Johnson, focused on innovative medicine and medtech. The company updates its logo and branding. #corporate #rebranding